Ordentlich Peter 4
4 · Syndax Pharmaceuticals Inc · Filed Aug 26, 2022
Insider Transaction Report
Form 4
Ordentlich Peter
Chief Technology Officer
Transactions
- Sale
Common Stock
2022-08-24$25.04/sh−22,846$571,966→ 265 total - Exercise/Conversion
Common Stock
2022-08-24$6.35/sh+2,154$13,678→ 2,419 total - Exercise/Conversion
Stock Options (Right to buy)
2022-08-24−22,846→ 0 totalExercise: $6.32Exp: 2024-09-15→ Common Stock (22,846 underlying) - Other
Common Stock
2022-07-29$14.12/sh+265$3,742→ 265 total - Exercise/Conversion
Common Stock
2022-08-24$6.32/sh+22,846$144,387→ 23,111 total - Sale
Common Stock
2022-08-24$25.04/sh−2,154$53,927→ 265 total - Exercise/Conversion
Stock Options (Right to buy)
2022-08-24−2,154→ 0 totalExercise: $6.35Exp: 2024-12-18→ Common Stock (2,154 underlying)
Footnotes (4)
- [F1]The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 265 shares by the Reporting Person on 07/29/2022 pursuant to the Issuer's Employee Stock Purchase Plan.
- [F2]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 255,647 options to purchase shares of common stock that are vested and immediately exercisable and a total of 148,194 options to purchase shares of common stock that have not yet vested.
- [F3]The sale prices ranged from $25.00 to $25.18.
- [F4]This option is fully vested.